Medical device company Abbott Laboratories (ABT), Wednesday announced the real-world data study outcome, which stated that GLP-1 medicines and FreeStyle Libre technology together had greater improvement in the HbA1c levels of Type 2 Diabetes patients.
HbA1c is a measurement of a person's average blood glucose level over three months.
The study report presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes, found that using GLP-1 and FreeStyle Libre technology together had significantly reduced HbA1c levels to -2.4 percent, compared to -1.7 percent when GLP-1 was used alone.
Currently, Abbott's stock is climbing 0.63 percent, to $119.23 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.